新闻通稿

主页/新闻通稿

Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be Featured on Biotalknology Webinar “Oral Delivery of Therapeutic Proteins – Oramed Story” on November 18, 2020

NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Nobel Laureate Prof. Avram Hershko and Oramed Chief Scientific Officer Dr. Miriam  Kidron will join Premas [...]

2020-11-12T08:40:00+00:00分类:新闻通稿|标签:|

Oramed to Present Phase 2b Oral Insulin Data at American Association of Pharmaceutical Scientists 2020 PharmSci 360 Conference

NEW YORK, Oct. 28, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it is presenting a poster at the 2020 American Association of Pharmaceutical Scientists (AAPS) 2020 [...]

2020-10-28T08:40:00+00:00分类:新闻通稿|标签:|

Oramed CEO Nadav Kidron & Premas Biotech to Host Webinar “The Journey of Oral Insulin: Oramed Story” on Wednesday October 28, 2020

NEW YORK, Oct. 27, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will join Premas Biotech's Co-Founder and Managing Director Dr. Prabuddha Kundu in [...]

2020-10-27T08:55:00+00:00分类:新闻通稿|标签:|

Oramed Issues Shareholder Update on Pivotal Phase 3 Oral Insulin Studies: Protocols Submitted to FDA

1,125 patients combined in both studies Efficacy data available after the 6-month dosing NEW YORK, Oct. 16, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the [...]

2020-10-16T08:40:00+00:00分类:新闻通稿|标签:|

Oramed Pharmaceuticals to Present at the European Association for the Study of Diabetes (EASD) Annual Meeting

Oral Presentation on Oral Insulin Effect on Diabetes and Poster Presentation on Oral Insulin Effect on NASH NEW YORK, Sept. 21, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, [...]

2020-09-21T08:25:00+00:00分类:新闻通稿|标签:|

Oramed’s Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients

91% of T1D patients and 85% of T2D patients surveyed indicated they were "extremely likely" or "very likely" to ask their doctors about ORMD-0801 NEW YORK, Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on [...]

2020-09-15T08:25:00+00:00分类:新闻通稿|标签:|

Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin

Data Presented at the American Diabetes Association Scientific Session 2020 NEW YORK, June 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its pilot study of its [...]

2020-06-15T08:25:00+00:00分类:新闻通稿|标签:|